A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis
{{output}}
Vedolizumab is a novel humanised monoclonal IgG1 antibody gut selective anti-integrin specifically targeting α4β7 integrins in the gut and found to be efficacious in the treatment of ulcerative colitis. Areas covered: Research investigating the cost-effectiv... ...
